BIOMERICA INC (BMRA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.31+4.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BMRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 18.2% |
Growth built into the price is above our model estimate.
The price assumes 85.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 88 industry peers
BMRA — private placement
Dated 2026-08-26
Entry into a Material Definitive Agreement. Private Placement On August 20, 2026, Biomerica, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company’s Board of Directors and executive officers (collectively, the “Purchasers”), pursuant to which…
Why it matters: The recent M&A activity could change the company's future. Updates can signal strategic shifts.
Watch forA press release says the acquired company is now part of us.
Also watch forNo news or bad updates about the acquisition's impact.
Why it matters: M&A activity may show growth chances for Biomerica. It could improve their market position.
Supportive ifA press release about new developments or partnerships from the recent M&A.
Worry ifNo news or bad news about the M&A activity.
Why it matters: A rise in sector growth could help Biomerica's performance and market views.
Watch forSector revenue growth speeds up again, above 9% year over year.
Also watch forSector revenue growth slows down below 9% year over year.
Why it matters: A drop in revenue would confirm that growth efforts are failing. Investors want to see revenue rise.
Worry ifQ3 revenue reported below $987,000.
Less concerning ifRevenue increases above $987,000 in Q3.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $505 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,344 loss on $10,000 · 53.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If operating income gets better than -$1,298,000, it shows improved cost control. This may make investors feel more positive.
Supportive ifOperating income is better than -$1,298,000.
Worry ifOperating income gets worse than -$1,298,000.
Why it matters: If operating income goes down, it shows management is not doing well. Investors want to see better results.
Worry ifIn Q3, operating income was worse than -$1,300,000.
Less concerning ifOperating income gets better and is less negative than -$1,300,000.
Why it matters: Details on the private placement could affect cash flow and future growth. Investors need clarity on funding.
Watch forThere is a press release about the private placement agreement results.
Also watch forThere are no updates or bad news about the private placement.
Why it matters: Steady revenue growth is important for Biomerica's future. It shows if management's plans are working.
Supportive ifQ3 revenue shows less than a 10% decline from $987,000.
Worry ifQ3 revenue declines more than 10% from $987,000.
Why it matters: Management is working to improve operating income. A positive change would show progress.
Supportive ifOperating income turns positive or gets better from -$1.53M in 2026-Q4.
Worry ifOperating income remains negative or worsens from -$1.53M in 2026-Q4.
Why it matters: Revenue has been going down. Stabilization or growth would show a turnaround.
Supportive ifRevenue increases from $876K in 2026-Q4 compared to prior quarters.
Worry ifRevenue continues to decline from $876K in 2026-Q4.
Why it matters: The private placement could provide needed funds. How it is used will be key.
Watch forManagement announces a clear plan for using funds from the private placement.
Also watch forNo clear plan is communicated for the use of funds from the private placement.